---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-22-000057"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2022-04-12T23:59:59+00:00"
generated_at: "2026-06-26T08:05:30.607273+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pfizer names David M. Denton as CFO effective May 2, 2022

## Summary
- David M. Denton named CFO, EVP effective May 2, 2022, succeeding Frank D'Amelio after 15-year career.
- Compensation: $1.25M base salary, $1.25M target cash incentive (pro-rated for 2022).
- One-time $5M cash payment (repayable if voluntary resignation within 1 year), RSUs valued at $3.25M, and $9.75M Supplemental Plan credit.
- Denton brings 20+ years healthcare experience; previously CFO at Lowe's and CVS Health.

## SEC filing metadata
- accession: 0000078003-22-000057
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2022-04-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800322000057/0000078003-22-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800322000057/pfe-20220411.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-22-000057
- JSON: https://secwatch.observer/filing/0000078003-22-000057.json
- Plain text: https://secwatch.observer/filing/0000078003-22-000057.txt

## Key facts
- Executive change
  Frank D'Amelio departed as Chief Financial Officer and Executive Vice President at PFIZER INC.
  - Action: leaving
  - Role: Chief Financial Officer and Executive Vice President
  source text: As previously reported by the Company in a Current Report on Form 8-K filed with the Securities and Exchange Commission on November 19, 2021, the Company announced that Frank D’Amelio will be leaving his position as Chief Financial Officer and Executive Vice President after a nearly 15-year distinguished career with the Company and that Mr. D’Amelio would continue to serve as CFO until the appointment of a new chief financial officer, and will stay on as a special advisor until as late as December 31, 2022 in order to ensure a smooth transition of his CFO responsibilities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800322000057/0000078003-22-000057-index.htm
- Executive change
  David M. Denton was elected as Chief Financial Officer, Executive Vice President at PFIZER INC.
  - Action: elected
  - Role: Chief Financial Officer, Executive Vice President
  source text: On April 11, 2022, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company elected David M. Denton as Chief Financial Officer, Executive Vice President of the Company and appointed Mr. Denton as a member of the Company's Executive Leadership Team, effective May 2, 2022 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800322000057/0000078003-22-000057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.